Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026
Monopar Therapeutics Inc. MNPR
$72.96
▼ -1.07%
($-0.79)
🔥 High Short Interest
🎈 Low Float
📅 Earnings This Week
Open
$73.16
Prev Close
$73.75
Day Range
$71.07 – $75.60
52W Range
$50.07 – $124.82
Market Cap
$495.02M
Beta
1.69
EPS (TTM)
$-2.17
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-12-19 |
| Shares Out. | 6,710,000 |
| Website | monopartx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 22 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$5.3M |
| Free Cash Flow | -$12.2M |
| Total Assets | $135.0M |
| Total Liabilities | $4.1M |
| Equity | $130.9M |
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Monopar Therapeutics Inc. is a publicly traded company under the ticker symbol MNPR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-11-01)